癌におけるKLF9:潜在的な予後マーカーと治療目標
Xiaoxiao Xiao1,2, Zhipeng Dai3, Fang Liu1
1Faculty of Chinese Medicine, Hunan Traditional Chinese Medical College, Zhuzhou, China.
Frontiers in oncology
|August 27, 2025
まとめ
クルペル様因子9 (KLF9) は,腫瘍抑制剤または腫瘍遺伝子として作用し,がんにおける二重の役割を示しています. KLF9の発現レベルは患者の治療結果を予測することができ,KLF9はパーソナライズされたがん薬の潜在的治療標的である.
科学分野:
- 分子生物学
- 腫瘍学
- 遺伝学
背景:
- クルペル様因子9 (KLF9) は,がんに関与する転写因子である.
- 腫瘍形成におけるその役割は文脈に依存し,腫瘍抑制剤または腫瘍遺伝子として作用する.
- KLF9は,がんの種類によって異なる発現を示し,患者の予後に影響を与えます.
研究 の 目的:
- 癌の発症と進行におけるKLF9の多面的な役割を検討する.
- KLF9を 診断用バイオマーカーと 治療用ターゲットとして強調する
- 将来の研究と パーソナライズされたがん治療の 洞察を提供するためです
主な方法:
- 癌におけるKLF9に関する最近の研究の文献レビュー.
- 腫瘍形成におけるKLF9の二重機能の分析
- バイオマーカーおよび治療目標としてのKLF9の臨床的意義の検討.
主要な成果:
- KLF9は,腫瘍抑制剤または腫瘍遺伝子として作用し,がんにおける文脈特有の機能を示す.
- 低KLF9発現はしばしば患者の不良結果と相関する.
- KLF9の調節は新しいがん治療法にとって有望な道を示しています
結論:
- KLF9はがんにおける重要な要因であり,有意な予後および治療的影響を及ぼします.
- KLF9の二重な役割を理解することは 効果的なパーソナライズされたがん治療の開発に不可欠です
- KLF9は将来のがん研究と精密医療戦略の重要なターゲットです.
さらに関連する動画
関連する概念動画
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K